News & Press

Filter by year:

A High-dose Pharmacokinetic Study of a New IgG4 Monoclonal Antibody Temelimab/GNbAC1 Antagonist of an Endogenous Retroviral Protein pHERV-W Env

Hervé Porchet, MD; Virginie Vidal, MSc; Gabrielle Kornmann, PhD; Sam Malpass, MSc; François Curtin, MD

GeNeuro to Present at 3rd 2019 HERVs & Disease International Workshop on Human Endogenous Retroviruses (HERVs) and Diseases

Geneva, Switzerland, October 31, 2019 – 7:30 am CET – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, such as multiple sclerosis (MS) and type-1 diabetes, announced that the company will present at and sponsor the 3 rd HERVs & Disease International Workshop on Human Endogenous Retroviruses and Diseases, to be held November 5-6, 2019, in Lyon, France.

GeNeuro: financial information and business update for the third quarter 2019

Geneva, Switzerland, October 25, 2019 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, such as multiple sclerosis (MS) and type-1 diabetes, reported today on its 2019 third quarter cash position and issued a business update.

GeNeuro Reports 2019 Half-Year Results and Provides Corporate Update

Geneva, Switzerland, September 30, 2019 at 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, such as multiple sclerosis (MS) and type-1 diabetes (T1D), today reported its half-year financial results for the period ending June 30, 2019 and provided a corporate update.

Le journal des biotechs

Carmat, Celyad, Hybrigenics, entretien avec Jesús Martin-Garcia, DG de Geneuro

GeNeuro’s temelimab shows extended neuroprotective effects in relapsing-remitting MS

Geneva, Switzerland, September 16, 2019 – 7:30 am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS) and type-1 diabetes (T1D), today announced that the neuroprotective effects of temelimab in MS patients extend to 96 weeks and that it is safe to use and well tolerated for a prolonged period. These data, from ANGEL-MS, an extension of the Phase 2 CHANGE-MS trial in relapsing-remitting MS (RRMS), were presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2019) Congress in Stockholm, Sweden.

ECTRIMS 2109 - Neuroprotective effects of temelimab in relapsing-remitting MS patients extend to 96 weeks

Phase IIb safety and efficacy data on temelimab at week 96 from the ANGEL-MS study

GeNeuro: financial information and business update for the second quarter 2019

Geneva, Switzerland, July 18, 2019, 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS) and type-1 diabetes (T1D), today reported on its 2019 second quarter cash position and issued a business update.

HERV: A BBC4 radio interview of Prof. Patrick Küry

...

GeNeuro: Frontiers in Genetics review supports role of hidden DNA viruses in neurological disorders

  


Results 1-10 of 21      Next Page      Last Page